BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17591770)

  • 41. The chaperonin TRiC/CCT is essential for the action of bacterial glycosylating protein toxins like
    Steinemann M; Schlosser A; Jank T; Aktories K
    Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9580-9585. PubMed ID: 30181275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.
    Ho JG; Greco A; Rupnik M; Ng KK
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18373-8. PubMed ID: 16344467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases.
    von Eichel-Streiber C; Sauerborn M; Kuramitsu HK
    J Bacteriol; 1992 Oct; 174(20):6707-10. PubMed ID: 1307487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crystal structure of Clostridium difficile toxin A.
    Chumbler NM; Rutherford SA; Zhang Z; Farrow MA; Lisher JP; Farquhar E; Giedroc DP; Spiller BW; Melnyk RA; Lacy DB
    Nat Microbiol; 2016 Jan; 1():15002. PubMed ID: 27571750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clostridium difficile Toxin Biology.
    Aktories K; Schwan C; Jank T
    Annu Rev Microbiol; 2017 Sep; 71():281-307. PubMed ID: 28657883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clostridium difficile toxins: more than mere inhibitors of Rho proteins.
    Genth H; Dreger SC; Huelsenbeck J; Just I
    Int J Biochem Cell Biol; 2008; 40(4):592-7. PubMed ID: 18289919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inverse control of Rab proteins by
    Ost GS; Wirth C; Bogdanović X; Kao WC; Schorch B; Aktories PJK; Papatheodorou P; Schwan C; Schlosser A; Jank T; Hunte C; Aktories K
    Sci Adv; 2020 Mar; 6(11):eaaz2094. PubMed ID: 32195351
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Schweitzer T; Genth H; Pich A
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077344
    [No Abstract]   [Full Text] [Related]  

  • 49. Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins.
    Genth H; Pauillac S; Schelle I; Bouvet P; Bouchier C; Varela-Chavez C; Just I; Popoff MR
    Cell Microbiol; 2014 Nov; 16(11):1706-21. PubMed ID: 24905543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.
    Zhang Y; Hamza T; Gao S; Feng H
    Biochem Biophys Res Commun; 2015 Apr; 459(2):259-263. PubMed ID: 25725153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EhRho1, a RhoA-like GTPase of Entamoeba histolytica, is modified by clostridial glucosylating cytotoxins.
    Majumder S; Schmidt G; Lohia A; Aktories K
    Appl Environ Microbiol; 2006 Dec; 72(12):7842-8. PubMed ID: 17056697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
    Chen B; Liu Z; Perry K; Jin R
    Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
    Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
    Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CPDadh: a new peptidase family homologous to the cysteine protease domain in bacterial MARTX toxins.
    Pei J; Lupardus PJ; Garcia KC; Grishin NV
    Protein Sci; 2009 Apr; 18(4):856-62. PubMed ID: 19309740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition.
    Hofmann F; Busch C; Aktories K
    Infect Immun; 1998 Mar; 66(3):1076-81. PubMed ID: 9488398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
    Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
    J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS.
    Albesa-Jové D; Bertrand T; Carpenter EP; Swain GV; Lim J; Zhang J; Haire LF; Vasisht N; Braun V; Lange A; von Eichel-Streiber C; Svergun DI; Fairweather NF; Brown KA
    J Mol Biol; 2010 Mar; 396(5):1260-70. PubMed ID: 20070948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transient expression of RhoA, -B, and -C GTPases in HeLa cells potentiates resistance to Clostridium difficile toxins A and B but not to Clostridium sordellii lethal toxin.
    Giry M; Popoff MR; von Eichel-Streiber C; Boquet P
    Infect Immun; 1995 Oct; 63(10):4063-71. PubMed ID: 7558320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.
    Li S; Shi L; Yang Z; Zhang Y; Perez-Cordon G; Huang T; Ramsey J; Oezguen N; Savidge TC; Feng H
    Infect Immun; 2015 Feb; 83(2):502-13. PubMed ID: 25404023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autoproteolytic activation of bacterial toxins.
    Shen A
    Toxins (Basel); 2010 May; 2(5):963-77. PubMed ID: 22069620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.